AUS
NZ
UK
CA
USA
IND
Healthcare
Monopar Therapeutics (NASDAQ:MNPR) Sharpens Focus on Molecular Targeting
December 29, 2025 12:00 AM PST| By Anmol KhazanchiMonopar Therapeutics (NASDAQ:MNPR) is a clinical-stage biotechnology company developing targeted radiotherapeutics and next-generation antibody-drug conjugates to enhance precision in cancer treatment.
Precigen (NASDAQ:PGEN) Advances Genetic Medicine Platforms
December 29, 2025 12:00 AM PST| By Anmol KhazanchiPrecigen (NASDAQ:PGEN) focuses on genetic medicines through proprietary gene and cell therapy platforms, supporting targeted treatments across oncology, infectious diseases, and rare medical conditions.
CeriBell Corp (NASDAQ:CBLL) Develops Integrated Hearing Solutions
December 29, 2025 12:00 AM PST| By Anmol KhazanchiCeriBell Corp (NASDAQ:CBLL) delivers automated newborn hearing screening solutions using OAE and ABR technologies, supporting early detection of auditory impairments across hospitals and clinical settings.
Glaukos Corp (NYSE:GKOS) Shares Rise After Quarterly Results
December 24, 2025 08:07 AM PST| By Anmol KhazanchiGlaukos Corporation (NYSE:GKOS) provides MIGS devices and drug-delivery technologies, combining precision medical engineering with innovative solutions for chronic eye disease management.
Pfizer Inc (NYSE:PFE) Advances Biopharmaceutical Operations Globally
December 24, 2025 08:00 AM PST| By Anmol KhazanchiPfizer Inc (NYSE:PFE) demonstrates operational strength in medicines and vaccines, with consistent quarterly earnings, global manufacturing, and structured dividend distribution in the biopharmaceutical sector.
Pfizer (NYSE:PFE) Shares Flat After Clinical Update Disclosure
December 24, 2025 04:45 AM PST| By Anmol KhazanchiAn overview of Pfizer Inc operations, research activity, manufacturing reach, and sector classification, highlighting its role within healthcare and references such as the S&P 500.
National Research Corp (NASDAQ:NRC) Nasdaq 100 Index Health Metrics
December 24, 2025 12:00 AM PST| By Anmol KhazanchiVEON delivers mobile, broadband, and digital services across emerging markets through its operating subsidiaries, maintaining visibility in broader market discussions connected to the nasdaq 100 index.
Arcellx Inc (NASDAQ:ACLX) Nasdaq Composite Platform-Driven Biotech
December 24, 2025 12:00 AM PST| By Anmol KhazanchiArcellx (NASDAQ:ACLX) develops modular cell therapy platforms focused on oncology and immune control, maintaining visibility in biotechnology conversations shaped by the nasdaq composite.
United Therapeutics (NASDAQ:UTHR) Nasdaq Index Targeted Biotech
December 24, 2025 12:00 AM PST| By Anmol KhazanchiUnited Therapeutics (NASDAQ:UTHR) strengthens specialized healthcare through targeted therapies for rare conditions, remaining prominent in biotechnology discussions shaped by activity across the nasdaq index.
AtriCure Inc (NASDAQ:ATRC) Nasdaq Index Medical Device Depth
December 24, 2025 12:00 AM PST| By Anmol KhazanchiAtriCure (NASDAQ:ATRC) develops specialized medical devices for cardiac rhythm disorders, remaining visible in healthcare conversations shaped by activity connected to the nasdaq index.
Masimo Corporation (NASDAQ:MASI) Nasdaq 100 Composition Health Tech
December 24, 2025 12:00 AM PST| By Anmol KhazanchiMasimo (NASDAQ:MASI) supports global healthcare through noninvasive monitoring technologies, appearing in broader market conversations shaped by developments within the nasdaq 100 composition.
Masimo Corporation (NASDAQ:MASI) Nasdaq 100 Composition Health Tech
December 24, 2025 12:00 AM PST| By Anmol KhazanchiMasimo (NASDAQ:MASI) supports global healthcare through noninvasive monitoring technologies, appearing in broader market conversations shaped by developments within the nasdaq 100 composition.
Innoviva Inc (NASDAQ:INVA) Nasdaq Composite ETF Therapy Royalties
December 24, 2025 12:00 AM PST| By Anmol KhazanchiInnoviva (NASDAQ:INVA) operates as a royalty-focused life sciences company tied to respiratory therapies, appearing in broader biotechnology conversations shaped by the nasdaq composite etf.
Dynavax Technologies (NASDAQ:DVAX) Nasdaq 100 Index Healthcare Focus
December 24, 2025 12:00 AM PST| By Anmol KhazanchiDynavax Technologies (NASDAQ:DVAX) focuses on immune-based vaccine development through proprietary platforms, remaining visible in broader healthcare discussions associated with the nasdaq 100 index.
Merck & Co., Inc (NYSE:MRK) S&P 500 Companies Biotech Footprint
December 24, 2025 12:00 AM PST| By Anmol KhazanchiMerck & Co., Inc. operates as a global biopharmaceutical leader with strengths in oncology, vaccines, and animal health, maintaining visibility among major healthcare firms grouped within s&p 500 companies.
Medtronic plc (NYSE:MDT) S&P 500 Today Global Healthcare Presence
December 24, 2025 12:00 AM PST| By Anmol KhazanchiMedtronic plc (NYSE:MDT) operates as a global medical technology leader across devices and therapies, appearing in broader healthcare market discussions shaped by activity linked to s&p 500 today.
Soleno Therapeutics Inc (NASDAQ:SLNO) Nasdaq today Biopharma Niche Growth
December 23, 2025 12:00 AM PST| By Anmol KhazanchiSoleno Therapeutics (NASDAQ:SLNO) focuses on precision medicine and rare disease research, maintaining visibility in broader healthcare discussions that appear alongside developments tracked in nasdaq today.
Simulations Plus Inc (NASDAQ:SLP) Nasdaq 100 Index Pharma Modeling
December 23, 2025 12:00 AM PST| By Team Kalkine MediaSimulations Plus (NASDAQ:SLP) delivers advanced modeling and simulation software for pharmaceutical and biotech research, appearing in broader market discussions connected to the nasdaq 100 index.
Syndax Pharmaceuticals (NASDAQ:SNDX) Nasdaq index Biotech Position
December 23, 2025 12:00 AM PST| By Anmol KhazanchiSyndax Pharmaceuticals (NASDAQ:SNDX) focuses on epigenetic oncology research through clinical-stage programs, appearing in biotechnology discussions shaped by activity across the nasdaq index.
Amicus Therapeutics (NASDAQ:FOLD) Nasdaq Futures Clinical Strategy
December 23, 2025 12:00 AM PST| By Anmol KhazanchiAmicus Therapeutics (NASDAQ:FOLD) develops treatments for rare diseases using pharmacological chaperones and gene therapy, appearing in broader biotech discussions shaped by nasdaq futures.
